Syneron Medical Ltd., the developers of non-invasive technology for body shaping, received FDA clearance along with 510 (K) pre-marketing clearance and CE Mark Certification in the European market for their Vela Smooth Platform. This is the first time that the FDA has cleared a treatment for the thigh circumferential reduction market. This clearance was given after the efficacy of Syneron's Vela Platform was proved by a random, multi-center clinical study conducted in the United States and Canada.

Study Highlights
a. Researchers studied 66 women patients aged between 21 to 62 years.
b. Their body mass indexes (BMIs) were different, from underweight to normal to overweight and obese and 73 per cent had normal BMIs.
c. Random treatment was given to one thigh and the other thigh was used as control.
d. The person who measured the circumference did not know which thigh was treated.
e. The average circumference of the treated thigh reduced by 1.9 cm (0.75 inch) with a range of 0.3 to 7.2 cm (0.12 to 2.8 inches).
f. The circumference reduced in the untreated thigh by 0.3 cm (0.12 inch) with a range of -2 cm (-0.78 inch).
g. All the measurements were taken after 3 to 4 weeks of the final treatment.
h. The difference in treated and untreated thigh was significant and proved the efficacy of this treatment.

Highlights of the Vela Platform
a. This is a non-invasive device for treating cellulite.
b. It is powered by the revolutionary elōs Technology.
c. It is safe and effective.
d. It involves the use of light energy at a controlled infrared wavelength to tissues, conducted radio frequency energy and mechanical manipulation of the skin and fat layer of the area to be treated.